VRDNViridian Therapeutics, Inc.

$2B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$944,000-42.1% YoY

Gross Profit

-$6M-683.8% margin

Operating Income

-$9M-969.4% margin

Net Income

-$9M-954.6% margin

EPS (Diluted)

$-4.40

QoQ Revenue Growth

-56.7%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$968,000

Balance Sheet

Total Assets

$77M

Total Liabilities

$16M

Stockholders' Equity

$61M

Cash & Equivalents

$32M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$944,000	$2M	-42.1%
Gross Profit	-$6M	-$3M	-90.6%
Operating Income	-$9M	-$6M	-55.4%
Net Income	-$9M	-$6M	-54.5%

Revenue Segments

Reimbursement Revenue

$848,00051%

Collaboration Revenue

$814,00049%

VRDN Q3 2018 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena